B

Barbara Ann Karmanos Cancer Institute | Detroit, MI

Research site
(Unclaimed)
Location
87 E Canfield MM03CT, Detroit, Michigan, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

56 of 567
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood ca...

Active, not recruiting
Multiple Myeloma
Lymphoma
Drug: Dexamethasone
Drug: Venetoclax

Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with rel...

Enrolling
Relapsed Solid Tumors
Refractory Solid Tumors
Drug: KB-0742

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

Enrolling
Neoplasms
Neoplasm Metastasis
Drug: EMB-01

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-c...

Enrolling
Multiple Myeloma
Drug: Cilta-cel

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended...

Active, not recruiting
Kidney Cancer
RCC
Drug: Cabozantinib
Drug: Nivolumab

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Niraparib
Drug: Pembrolizumab

The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (pat...

Active, not recruiting
Colorectal Neoplasms
Drug: Ipilimumab
Drug: Atezolizumab

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or...

Active, not recruiting
Chronic Graft-versus-host-disease
Drug: Axatilimab

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administratio...

Enrolling
Multiple Myeloma
Drug: Cyclophosphamide
Drug: Cilta-cel

The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criter...

Active, not recruiting
ALK-positive Advanced NSCLC
Drug: Brigatinib

This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administ...

Enrolling
Metastatic Cancer
Solid Tumor
Biological: CF33-hNIS
Biological: Pembrolizumab

This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advan...

Active, not recruiting
Solid Tumor
Colorectal Adenocarcinoma
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimen...

Enrolling
Amyloidosis
Drug: Cyclophosphamide
Drug: Dexamethasone

The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and...

Enrolling
Solid Tumors
Drug: Nivolumab
Drug: DF6002

This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: DS-9606a

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Colon Cancer
Drug: Fruquintinib
Drug: Placebo
Recently updated

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/re...

Active, not recruiting
Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Drug: ION251

This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in co...

Enrolling
Metastatic Pancreatic Adenocarcinoma
Drug: Capecitabine
Drug: Ivaltinostat

Trial conditions

Lung Cancer (60 trials)
Lymphoma (55 trials)
Breast Cancer (52 trials)
Leukemia (47 trials)
Multiple Myeloma (47 trials)
Non-Small-Cell Lung Carc... (42 trials)
Plasma Cell Cancer (39 trials)
Cancer (38 trials)
Prostatic Cancer (37 trials)
Head and Neck Cancer (29 trials)

And 90 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems